Veradigm Inc. (NASDAQ:MDRX - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.00.
Separately, StockNews.com started coverage on shares of Veradigm in a report on Thursday, October 24th. They set a "hold" rating on the stock.
Read Our Latest Report on Veradigm
Veradigm Price Performance
Veradigm stock remained flat at $9.25 on Tuesday. 3,423 shares of the company's stock were exchanged, compared to its average volume of 1,656,559. The company's fifty day moving average is $9.53 and its two-hundred day moving average is $9.13. Veradigm has a 52-week low of $5.01 and a 52-week high of $13.62.
Institutional Trading of Veradigm
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC bought a new stake in Veradigm in the second quarter valued at about $38,000. Tyro Capital Management LLC bought a new stake in Veradigm in the first quarter valued at about $9,055,000. Meadow Creek Wealth Advisors LLC bought a new stake in Veradigm in the first quarter valued at about $83,000. Finally, Vanguard Group Inc. increased its stake in Veradigm by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,275,875 shares of the software maker's stock valued at $149,754,000 after acquiring an additional 95,291 shares during the period.
Veradigm Company Profile
(
Get Free ReportVeradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Further Reading
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
